Mediastinitis medical therapy: Difference between revisions
Jump to navigation
Jump to search
m (Changes made per Mahshid's request) |
|||
| (7 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Mediastinitis}} | {{Mediastinitis}} | ||
{{CMG}} | {{CMG}} {{AE}} {{AG}} | ||
==Overview== | ==Overview== | ||
The mainstay of therapy in acute mediastinitis secondary to cardiothoracic surgery includes [[ | The mainstay of therapy in acute mediastinitis secondary to cardiothoracic surgery includes [[clindamycin]] and [[ceftriaxone]]. The preferred regimen for preoperative [[prophylaxis]] against acute mediastinitis includes either a second generation [[cephalosporin]] or [[vancomycin]]. Descending necrotizing mediastinitis is a very serious complication of [[oropharyngeal]] infections that should be treated promptly with early and aggressive surgical debridement and broad spectrum antibiotics that provide coverage against [[Methicillin-resistant staphylococcus aureus|MRSA]], beta-lactamase producing [[gram-negative bacteria|gram-negative organisms]], and [[anaerobes]]. | ||
==Medical Therapy== | ==Medical Therapy== | ||
| Line 26: | Line 26: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Pulmonology]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 18:02, 18 September 2017
|
Mediastinitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mediastinitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Mediastinitis medical therapy |
|
Risk calculators and risk factors for Mediastinitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anthony Gallo, B.S. [2]
Overview
The mainstay of therapy in acute mediastinitis secondary to cardiothoracic surgery includes clindamycin and ceftriaxone. The preferred regimen for preoperative prophylaxis against acute mediastinitis includes either a second generation cephalosporin or vancomycin. Descending necrotizing mediastinitis is a very serious complication of oropharyngeal infections that should be treated promptly with early and aggressive surgical debridement and broad spectrum antibiotics that provide coverage against MRSA, beta-lactamase producing gram-negative organisms, and anaerobes.
Medical Therapy
Antimicrobial Regimens
- 1. Post-cardiothoracic surgery mediastinitis[1]
- 1.1 Treatment
- Preferred regimen: Clindamycin 450 mg IV q6h AND Ceftriaxone 2 g IV q24h for > 2 weeks
- Note: A deep sternal wound infection should be treated with aggressive surgical debridement in the absence of complicating circumstances.
- 1.2 Prophylaxis
- 1.2.1 Methicillin susceptible staphylococcus aureus
- Preferred regimen: Cefazolin 2 g IV single dose OR Cefoxitin 2 g IV single dose OR Cefuroxime 1.5 g IV single dose
- 1.2.2 Methicillin resistant staphylococcus aureus
- Preferred regimen: Vancomycin 15 mg/kg IV single dose
- Note (1): Preoperative antibiotics should be administered to all patients to reduce the risk of mediastinitis in cardiac surgery.
- Note (2): The use of intranasal mupirocin is reasonable in nasal carriers of S. aureus.
- 2. Descending necrotizing mediastinitis
- Preferred regimen (1): Vancomycin 2 g/day IV q6-12h (trough levels 15-20 mg/L) AND Imipenem 500 mg IV q6h
- Preferred regimen (2): Vancomycin 2 g/day IV q6-12h (trough levels 15-20 mg/L) AND Meropenem 1 g IV q8h
- Preferred regimen (3): Vancomycin 2 g/day IV q6-12h (trough levels 15-20 mg/L) AND Piperacillin-Tazobactam 3.375 g IV q6h
- Note: The mainstay of therapy for descending necrotizing mediastinitis is surgical debridement.
References
- ↑ Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons". J Am Coll Cardiol. 58 (24): e123–210. doi:10.1016/j.jacc.2011.08.009. PMID 22070836.